158 related articles for article (PubMed ID: 7768001)
41. Co-administration of polyanions with a phosphorothioate oligodeoxynucleotide (CGP 69846A): a role for the scavenger receptor in its in vivo disposition.
Steward A; Christian RA; Hamilton KO; Nicklin PL
Biochem Pharmacol; 1998 Aug; 56(4):509-16. PubMed ID: 9763228
[TBL] [Abstract][Full Text] [Related]
42. Modification of phosphorothioate oligonucleotides yields potent analogs with minimal toxicity for antisense experiments in the CNS.
Peng Ho S; Livanov V; Zhang W; Li J; Lesher T
Brain Res Mol Brain Res; 1998 Nov; 62(1):1-11. PubMed ID: 9795101
[TBL] [Abstract][Full Text] [Related]
43. Antimycobacterial activities of antisense oligodeoxynucleotide phosphorothioates in drug-resistant strains.
Rapaport E; Levina A; Metelev V; Zamecnik PC
Proc Natl Acad Sci U S A; 1996 Jan; 93(2):709-13. PubMed ID: 8570621
[TBL] [Abstract][Full Text] [Related]
44. Pharmacokinetics of a tumor necrosis factor-alpha phosphorothioate 2'-O-(2-methoxyethyl) modified antisense oligonucleotide: comparison across species.
Geary RS; Yu RZ; Watanabe T; Henry SP; Hardee GE; Chappell A; Matson J; Sasmor H; Cummins L; Levin AA
Drug Metab Dispos; 2003 Nov; 31(11):1419-28. PubMed ID: 14570775
[TBL] [Abstract][Full Text] [Related]
45. In vivo distribution and metabolism of a phosphorothioate oligonucleotide within rat liver after intravenous administration.
Graham MJ; Crooke ST; Monteith DK; Cooper SR; Lemonidis KM; Stecker KK; Martin MJ; Crooke RM
J Pharmacol Exp Ther; 1998 Jul; 286(1):447-58. PubMed ID: 9655890
[TBL] [Abstract][Full Text] [Related]
46. Antisense gene inhibition by oligonucleotides containing C-5 propyne pyrimidines.
Wagner RW; Matteucci MD; Lewis JG; Gutierrez AJ; Moulds C; Froehler BC
Science; 1993 Jun; 260(5113):1510-3. PubMed ID: 7684856
[TBL] [Abstract][Full Text] [Related]
47. Comparative pharmacokinetics, tissue distribution, and tumor accumulation of phosphorothioate, phosphorodithioate, and methylphosphonate oligonucleotides in nude mice.
DeLong RK; Nolting A; Fisher M; Chen Q; Wickstrom E; Kligshteyn M; Demirdji S; Caruthers M; Juliano RL
Antisense Nucleic Acid Drug Dev; 1997 Apr; 7(2):71-7. PubMed ID: 9149842
[TBL] [Abstract][Full Text] [Related]
48. Long-term treatment of human immunodeficiency virus-infected cells with antisense oligonucleotide phosphorothioates.
Lisziewicz J; Sun D; Metelev V; Zamecnik P; Gallo RC; Agrawal S
Proc Natl Acad Sci U S A; 1993 May; 90(9):3860-4. PubMed ID: 8483903
[TBL] [Abstract][Full Text] [Related]
49. Antiviral activity and ocular kinetics of antisense oligonucleotides designed to inhibit CMV replication.
Henry SP; Miner RC; Drew WL; Fitchett J; York-Defalco C; Rapp LM; Levin AA
Invest Ophthalmol Vis Sci; 2001 Oct; 42(11):2646-51. PubMed ID: 11581212
[TBL] [Abstract][Full Text] [Related]
50. In vitro pharmacokinetics of phosphorothioate antisense oligonucleotides.
Crooke RM; Graham MJ; Cooke ME; Crooke ST
J Pharmacol Exp Ther; 1995 Oct; 275(1):462-73. PubMed ID: 7562586
[TBL] [Abstract][Full Text] [Related]
51. Spinal distribution and metabolism of 2'-O-(2-methoxyethyl)-modified oligonucleotides after intrathecal administration in rats.
Butler M; Hayes CS; Chappell A; Murray SF; Yaksh TL; Hua XY
Neuroscience; 2005; 131(3):705-15. PubMed ID: 15730875
[TBL] [Abstract][Full Text] [Related]
52. Capped oligodeoxynucleotide phosphorothioates. Pharmacokinetics and stability in mice.
Temsamani J; Tang JY; Agrawal S
Ann N Y Acad Sci; 1992 Oct; 660():318-20. PubMed ID: 1340145
[No Abstract] [Full Text] [Related]
53. Pharmacokinetics and blood-brain barrier transport of [3H]-biotinylated phosphorothioate oligodeoxynucleotide conjugated to a vector-mediated drug delivery system.
Wu D; Boado RJ; Pardridge WM
J Pharmacol Exp Ther; 1996 Jan; 276(1):206-11. PubMed ID: 8558431
[TBL] [Abstract][Full Text] [Related]
54. Cationic lipids enhance cellular uptake and activity of phosphorothioate antisense oligonucleotides.
Bennett CF; Chiang MY; Chan H; Shoemaker JE; Mirabelli CK
Mol Pharmacol; 1992 Jun; 41(6):1023-33. PubMed ID: 1352033
[TBL] [Abstract][Full Text] [Related]
55. Rapid plasma clearance and metabolism in vivo of a phosphorothioate oligodeoxynucleotide with a single, internal phosphodiester bond.
Boado RJ; Kang YS; Wu D; Pardridge WM
Drug Metab Dispos; 1995 Nov; 23(11):1297-300. PubMed ID: 8591734
[No Abstract] [Full Text] [Related]
56. Design of antisense oligonucleotides stabilized by locked nucleic acids.
Kurreck J; Wyszko E; Gillen C; Erdmann VA
Nucleic Acids Res; 2002 May; 30(9):1911-8. PubMed ID: 11972327
[TBL] [Abstract][Full Text] [Related]
57. Uptake, intracellular distribution, and stability of oligodeoxynucleotide phosphorothioate by Schistosoma mansoni.
Tao LF; Marx KA; Wongwit W; Jiang Z; Agrawal S; Coleman RM
Antisense Res Dev; 1995; 5(2):123-9. PubMed ID: 7580116
[TBL] [Abstract][Full Text] [Related]
58. Stability of polycationic complexes of an antisense oligonucleotide in rat small intestine homogenates.
González Ferreiro M; Crooke RM; Tillman L; Hardee G; Bodmeier R
Eur J Pharm Biopharm; 2003 Jan; 55(1):19-26. PubMed ID: 12551700
[TBL] [Abstract][Full Text] [Related]
59. Antisense oligodeoxynucleotide phosphorothioate complementary to Gag mRNA blocks replication of human immunodeficiency virus type 1 in human peripheral blood cells.
Lisziewicz J; Sun D; Weichold FF; Thierry AR; Lusso P; Tang J; Gallo RC; Agrawal S
Proc Natl Acad Sci U S A; 1994 Aug; 91(17):7942-6. PubMed ID: 8058738
[TBL] [Abstract][Full Text] [Related]
60. Pharmacokinetics and distribution of a 33P-labeled anti-human immunodeficiency virus oligonucleotide (AR177) after single- and multiple-dose intravenous administration to rats.
Wallace TL; Bazemore SA; Holm K; Markham PM; Shea JP; Chaudhary N; Cossum PA
J Pharmacol Exp Ther; 1997 Mar; 280(3):1480-8. PubMed ID: 9067338
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
